loading...

Gilead analysis shows remdesivir reduced coronavirus death risk, more studies needed

Gilead analysis shows remdesivir reduced coronavirus death risk, more studies neededRemdesivir has been at the forefront of the global battle against COVID-19 after the intravenously administered medicine helped shorten hospital recovery times, according to data in April from a separate U.S. government trial. In the latest analysis, Gilead said it analyzed data from 312 patients treated in its late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity. Gilead's late-stage study evaluated the safety and efficacy of five-day and 10-day dosing durations of remdesivir in hospitalized patients.




from Yahoo News - Latest News & Headlines https://ift.tt/2CrabuA

0 komentar

adnow

loading...